Titlebook: Anticancer Drug Development Guide; Preclinical Screenin Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 cancer.c

Host142

Models for Minimal Residual Tumor been in leukemia, lymphoma, and selected solid tumors, such as testis cancer. The administration of very high doses of chemotherapy requiring hematopoietic stem-cell support has had more than a 10-year history (.). Even with this heroic treatment, cure of solid tumors, such as breast cancer and sma

小樣他閑聊

Spontaneously Occurring Tumors in Companion Animals as Models for Drug Developmenterapies. The majority of this work has been performed on inbred rodent models and laboratoryderived canine populations. Working with inbred populations in controlled, artificial laboratory environments raises some degree of concern over the applicability of information as it relates to naturally occ

本土

Working with the National Cancer Institutenters (DCTDC). The Developmental Therapeutics Program (DTP) of DCTDC promotes all aspects of the discovery and preclinical development of new compounds as drugs. Its activities include demonstration of antiproliferative activity in vitro through its 60 human tumor cell line screen and in vivo using

Needlework

Phase I Trial Design and Methodologyrmamentarium of cancer therapeutics. Hence, the design, implementation, and analyses of a Phase I study must be viewed with a critical eye, acknowledging the limitations of this approach in determining the ultimate fate of a new agent. The overall objectives, design, and methodology of the clinical

別名

CARK

Drug Development in Europe potassium arsenite (Fowlers solution) given systemically was reported to have dramatic, although transient, effects on leukemias and lymphomas in the mid-19th century (.). One of the early “breakthroughs” came from studies in the UK on synthetic estrogens, which in the 1930s had been shown to inhib

拔出

FDA Role in Cancer Drug Development and Requirements for Approvalobjective of this chapter is to describe the role of the US Food and Drug Administration (FDA) in the development process and to discuss the requirements for approval of new cancer drugs. The new drug development process is illustrated in Fig. 1.

慷慨援助

一再困擾

,Funktionen mehrerer Ver?nderlicher,the tumor would behave in the rodent in a similar manner as it did in the patient. Such models would be useful for the individual patient treatment design and for evaluation of new antineoplastic agents and procedures.

痛打

Human Tumor Xenograft Models in NCI Drug Developmentxpedite the development of active lead compounds that may provide more efficacious treatments for human malignancy, but also to eliminate agents that are inactive and/or highly toxic from further consideration.